Device Vascular Embolization

Concertotm

Payments companies reported to CMS as associated with Concertotm. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$414Kassociated payments (2023-2025)
1,797clinicians with associated payments
1company reporting

By year

2023 $136K
2024 $108K
2025 $170K

Payments reported as associated with Concertotm, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular & Interventional Radiology $305K
Diagnostic Radiology $39K
Vascular Surgery $19K
Orthopaedic Surgery of The Spine $9,200
Interventional Cardiology $7,706
Cardiovascular Disease $3,204

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Concertotm

These are the largest totals companies reported as associated with Concertotm. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Gary Siskin Albany, NY Vascular & Interventional Radiology $44,503.23
Gloria Salazar Chapel Hill, NC Vascular & Interventional Radiology $35,890.12
Jessica Stewart Los Angeles, CA Vascular & Interventional Radiology $35,776.74
Anuj Malhotra Albany, NY Vascular & Interventional Radiology $27,629.45
Antony Gayed Greenville, SC Vascular & Interventional Radiology $16,577.40
Guillermo Gonzalez-Araiza Saint Louis, MO Vascular & Interventional Radiology $12,451.84
Jeffrey Ramkaransingh Indianapolis, IN Vascular & Interventional Radiology $11,380.63
Charles Martin Cleveland, OH Vascular & Interventional Radiology $10,726.89
Suvranu Ganguli Boston, MA Vascular & Interventional Radiology $9,840.92
Dania Daye Framingham, MA Vascular & Interventional Radiology $9,551.93

Prescribed Concertotm?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.